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Mapping and possible diagnostic meaning of a highly conserved, linear NS4 epitope (NS4/3), located outside the C100-3
antigen within the carboxyl terminal proportion of the NS4 region, with major immunoreactivity with specimens of patients
with HCV infection from various geographic origins is described. Transient, acute-phase IgM anti-HCV NS4/3 was detected
coincidentally or earlier than active IgG anti-HCV NS4/3 response with four well-characterized seroconversion panels.
GenBank alignment studies identified patch homologies between the NS4/3 sequence and a number of non-HCV proteins,
which may explain part of the cross-reactivity of the NS4/3 epitope. Some of the ‘‘false positive reactivities’’ of the NS4/3
epitope with asymptomatic blood donors, not being confirmed with FDA-approved anti-HCV assays without the NS4/3
epitope, may be explained by recognition of very early seroconversion antibodies. © 1998 Academic Press
INTRODUCTION
Hepatitis C virus (HCV) is the major causative agent of
posttransfusion non-A, non-B hepatitis (NANB) (Choo et
al., 1989). The detection of clone 5-1-1 (aa 1683–1735)
from the nonstructural region (NS4: aa 1658–1972) lead
to the identification of the HCV genome. The C-100-3
antigen (aa 1569–1931) was constructed by combination
of several overlapping clones surrounding clone 5-1-1.
The detection of antibody to the HCV C100-3 antigen was
the first useful marker developed to detect past or po-
tentially active infection with the hepatitis C virus
(Houghton, 1989; Kuo et al., 1989). Antibodies to the HCV
C100-3 antigen were found to appear rather late after
infection with HCV (Alter, 1994). A systematic epitope
survey of the structural and nonstructural region has
uncovered other immunogenic antigens mainly from the
NS3-region (C33-c antigen: aa 1192–1457) and from the
Core-region (C22-c antigen: aa 2–120), which are of great
importance in the early diagnosis of acute infections (van
der Poel et al., 1992).
Epitopes of the structural and nonstructural region
of HCV were identified by two different strategies;
overlapping sequences of HCV proteins were either
expressed by recombinant methods in foreign host
cells or were chemically synthesized and then
scanned with anti-virus antibodies for specific reactiv-
ity. Discontinuous epitopes, such as the major
epitopes of the NS3-region, can be identified only by
epitope mapping approaches with recombinant
polypeptides (Ihlenfeldt, 1995). Mapping and analysis
of linear epitopes can be performed in detail by use of
multiple peptide synthesis (Wienhues et al., 1998).
Linear epitopes with high immunoreactivity were
mapped mainly at the amino terminus of the core
region of HCV, within the sequence of C22-c, and in
the NS4 region, within the sequence of C100-3 (Ihlen-
feldt, 1995; Khudyakov et al., 1995; Park et al., 1995;
Pujol et al., 1996).
Here we describe the identification and immunological
characterization of a linear NS4 epitope (NS4/3), located
outside the C100-3 antigen at the carboxyl terminus of
the NS4 region. It shows major immunoreactivity with
specimens of patients with HCV infection from various
geographic origins. Mapping of this epitope, located out-
side the 5-1-1 antigen, has rarely been described (Flege-
lo´va et al., 1994; Park et al., 1995; Khudyakov et al., 1995).
An immunological characterization of this highly con-
served epitope and its diagnostic meaning are pre-
sented. Reactivity of NS4/3 with low-affinity IgM antibod-
ies present during the acute phase of HCV infection, as
well as with naturally occuring antibodies of asymptom-
atic blood donor specimens, is demonstrated.
RESULTS
Mapping of four major epitopes on NS4 protein
of HCV by multiple peptide synthesis
The NS4 region (aa 1658–1972) of HCV (isolate
HCV-1, genotype 1, subtype 1a) was scanned with
12-mer peptides and a 9-amino-acid overlap using pin
ELISA and 10 human anti-HCV-positive sera. Three
major epitopes were mapped within the sequence of1 To whom reprint requests should be addressed.
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the C100-3 antigen: NS4/0 (aa 1689–1706), NS4/1 (aa
1710–1727), and NS4/2 (aa 1722–1739) and one addi-
tional epitope with high immunoreactivity located out-
side the sequence of C100-3 antigen: NS4/3 (aa 1923–
1940) (data not shown).
In order to gain access to epitopes that are longer than
12 amino acids or that may be missed by use of the pin
ELISA due to interactions of pin peptides and solid phase
(Kraas et al., 1995; Wienhues et al., 1998), mapping of NS4
epitopes was further performed with 25-mer biotinylated
peptides and a 15-amino-acid overlap. Because of the spe-
cific streptavidin–biotin interaction, nonspecific binding is
greatly reduced. Antibody interactions with biotinylated
peptides do occur in a very flexible way in solution. Scan-
ning the NS4 region (aa 1616–2018) of HCV (isolate HCV-1,
genotype 1, subtype 1a) with 25-mer peptides with the
streptavidin–biotin ELISA and seven human anti-HCV-pos-
itive sera confirmed essentially the location of the major
epitopes identified by use of the 12-amino-acid pin pep-
tides. Two major linear epitopes were found to be located
within the 5-1-1 antigen sequence: NS4/1: aa 1694–1728
(scanned with 12-mer peptides: 1710–1727) and NS4/2: aa
1714–1748 (scanned with 12-mer peptides: aa 1722–1739);
one immunodominant linear epitope was found at the car-
boxy terminus of the C100-3 antigen sequence: NS4/3: aa
1914–1948 (scanned with 12-mer peptides: aa 1923–1940)
(Table 1). Additional minor epitopes reacted only with single
sera and could not be confirmed by both methods: pin
peptide scan with 9-mer peptides and biotin–peptide ELISA
with 25-mer peptides.
TABLE 1
Scan of the NS4 Protein with 25-mer Biotinylated Peptides and a 15-Amino-Acid Overlap
Region
Peptide
No. Location (aa) Sequences
Reactivity with
7 anti-HCV-
positive sera P/N
NS4: 1620–2016 16G4 1616–1638 PTLHGPTPLLYRLRGAVQNEITLT 1/7 9
16G5 1624–1648 LLYRLGAVQNEITLTHPVTKYIMTC 1/7 6
16G6 1634–1658 EITLTHPVTKYIMTCMSADLEVVTS
16H1 1644–1668 YIMTCMSADLEVVTSTWVLVGGVLA
16H2 1654–1678 EVVTSTWVLVGGVLAALAAYCLSTG 1/7 5
18G6 1664–1688 GGVLAALAAYCLSTGCVVIVGRVVL
18H1 1674–1698 CLSTGCVVIVGRVVLSGKPAIIPDR
5-1-1: 1683–1735 18H2 1684–1708 GRVVLSGKPAIIPDREVLYREFDEM 1/7 4
NS4/1: 1694–1728 18H3 1694–1718 IIPDREVLYREFDEMEECSQHLPYI 3/7 15
18H4 1704–1728 EFDEMEECSQHLPYIEQGMMLAEQF 2/7 10
NS4/2: 1714–1748 18H5 1714–1738 HLPYIEQGMMLAEQFKQKALGLLQT 5/7 16
20D3 1724–1748 LAEQFKQKALGLLQTASRQAEVIAP 3/7 13
20D4 1734–1758 GLLQTASRQAEVIAPAVQTNWQKLE
20D5 1744–1768 EVIAPAVQTNWQKLETFWAKHMWNF
20D6 1754–1778 WQKLETFWAKHMWNFISGIQYLAGL
20E1 1763–1787 KHMWNFISGIQYLAGLSTLPGNPAI
20E2 1773–1797 QYLAGLSTLPGNPAIASLMAFTAAV 1/7 10
20E 1783–1807 GNPAIASLMAFTAAVTSPLTTSQTL
20E4 1793–1817 FTAAVTSPLTTSQTLLFNILGGWVA
20E5 1803–1827 TSQTLLFNILGGWVAAQLAAPGAAT
20E6 1813–1837 SGWVAAQLAAPGAATAFVGAGLAGA
20F1 1823–1847 PGAATAFVGAGLAGAAIGSVGLGKV
20F2 1833–1857 GLAGAAIGSVGLGKVLIDILAGYGA
20F3 1843–1867 GLGKVLIDILAGYGAGVAGALVAFK
20F4 1853–1877 AGYGAGVAGALVAFKIMSGEVPSTE
20F5 1863–1887 LVAFKIMSGEVPSTEDLVNLLPAIL
20F6 1873–1897 VPSTEDLVNLLPAILSPAGALVVGFVV
20G1 1883–1907 LPAILSPGALVVGVVCAAILRRHVG
20G2 1893–1917 VVGVVCAAILRRHVGPGEGAVQWMN
20G3 1903–1927 RRHVGPGEGAVQWMNRLIAFASRGN
NS4/3: 1914–1948 20G4 1914–1938 QVWMNRLIAFASRGNHVSPTHYVPE 5/7 16
20G5 1924–1948 ASRGNHVSPTHYVPESDAAARVTAI 6/7 14
20G6 1934–1958 HYVPESDAAARVTAILSSLTVTQLL
20H1 1944–1968 RVTAILSSLTVTQLLRRLHQWISSE
20H2 1954–1978 VTQLLRRLHQWISSECTTPCSGSWL
21D6 1964–1988 WISSECTTPCSGSWLRDIWDWICEV
21E1 1974–1998 GSGWLRDIWDWICEVLSDFKTWLKA
21E2 1984–2008 WICEVLSDFKTWLKAKLMPQLPGIF
21E3 1994–2018 WLKAKLMPQLPGIPFVSCQRGYKGV 1/7 6
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Immunological characterization of the carboxy
terminal HCV-NS4 (NS4/3) epitope
We became interested in the rather unknown NS4/3
epitope because of its high immunoreactivity though
being located outside the already known immunodomi-
nant region of NS4: 5-1-1, which is included in several
diagnostic assays. We decided to further analyze the
immunological properties of this epitope.
Fine-tuning sensitivity and specificity
A systematic minimization of NS4/3 was performed
starting from the C-terminus, as well as from the N-
terminus (Table 2). The reactivity of the minimized pep-
tides was tested with 1 negative and 23 HCV-positive
and sera by use of the streptavidin–biotin ELISA. It ap-
pears that the core epitope is represented by just three
amino acids: PTH and the presence of S at the N-
terminus or Y at the C-terminus restores virtually all the
activity. Thus the minimal epitope might be defined as a
pentamer SPTHY (aa 1930–34).
Scanning the reactivity of the minimized peptides with
a larger panel of anti-HCV-positive sera the best sensi-
tivity was found with a synthetic peptide 10 amino acids
in length: HVSPTHYVPE (aa 1928–1937).
The specificity of NS4/3 could be improved by further
elongation to a 18-mer peptide with the sequence SRGN-
HVSPTHYVPESDAA (aa 1924–1941). When 2000 asymp-
tomatic blood donors were screened with the 10-mer
peptide (aa 1928–1937) with the streptavidin–biotin
ELISA, 17 specimens were identified that reacted posi-
tively with this peptide only and were not confirmed to be
reactive with commercial anti-HCV assays containing
C22-c, C33-c, and C100-3, but no NS4-3. Only 5 of these
17 specimens being reactive with the 10-mer peptides
were found to be still reactive with the 18-mer peptide; all
of them contained low titers of HCV RNA (data not
shown).
Thus the result of optimization of the sensitivity and
specificity of the NS4/3 epitope by fine-tuning the se-
quence length was the 18-mer peptide (aa 1924–1941).
Reacitivity of anti-HCV-positive sera of different
geographic origin
To further unravel the diagnostic significance of the
NS4/3 epitope the reactivity of the length-optimized pep-
tide (aa 1924–1941) was assessed with specimens that
were preselected due to their specific reactivity with
commercially available, FDA-approved anti-HCV assays.
To obtain a broad reactivity spectrum of the C-terminally
located NS4/3 epitope in comparison to the reactivity of
two synthetic epitopes located within the 5-1-1 antigen
(NS4/1, aa 1712–1720, and NS4/2, aa 1730–1738) a panel
of sera of different geographic origins was tested. All
sera from German and North American patients, as well
as the Egyptian sera, were found to show a predominant
immunoreactivity with the NS4/3 epitope (Table 3).
Sequence alignments of available isolates of different
subtypes of HCV showed a rather conserved sequence
of NS4/3 (Table 4). In contrast to the well-conserved
NS4/3 sequence, sequence alignments of available iso-
lates of different subtypes of HCV of NS4/1 and NS4/2
resulted in a big variation within the various HCV isolates
(Table 4). Thus to obtain a broad reactivity with various
HCV subtypes of different geographic origins NS4/3 ap-
pears to be a suitable epitope.
Reactivity of patients with acute HCV infection
Immunological reactivity with specimens of acutely
infected blood donors is of great importance in reducing
the risk of virus transmission.
TABLE 2
Testing of 23 Anti-HCV-Positive Sera against Peptide Antigens of
the Identified NS4/3 Epitope of HCV-1 of Variant Length (4–10 Amino
Acids)
Location
(aa)
NS4/3
sequence
Reactivity with
23 anti-HCV-
positive sera P/N
1928–1937 HVSPTHYVPE 20/23 23.3 (8.1–34.0)
1928–1936 HVSPTHYVP 20/23 22.1 (5.7–34.3)
1928–1935 HVSPTHYV 18/23 23.3 (7.4–32.4)
1928–1934 HVSPTHY 17/23 23.5 (5.9–36.4)
1928–1933 HVSPTH 11/23 16.8 (9.6–26.1)
1928–1932 HVSPT 2/23 14.4 (6.1–16.8)
1928–1931 HVSP 2/23 11.9 (7.0; 16.8)
1928–1937 HVSPTHYVPE 20/23 22.7 (8.1–33.9)
1929–1937 VSPTHYVPE 20/23 23.3 (5.2–36.0)
1930–1937 SPTHYVPE 18/23 18.9 (6.2–38.0)
1931–1937 PTHYVPE 10/23 19.2 (5.6–30.7)
1932–1937 THYVPE 4/23 14.0 (5.7–26.6)
1933–1937 HYVPE 4/23 14.0 (8.0–24.2)
1934–1937 YVPE 2/23 14.0 (5.2; 11.8)
TABLE 3
Assessment of the Reactivity of Sera from Various Geographic
Origins against the NS4 Epitopes
Epitope region NS4/1 NS4/2 NS4/3
Reactivity with 195 sera from German and North American patients
Reactive sera of 195
HCV-positive sera (n) 44 38 159
Percentage of reactive
HCV-positive sera 22.5% 19.5% 81.5%
Reactivity with 60 sera from Egyptian patients
Reactive sera of 60
HCV-positive sera (n) 3 4 46
Percentage of reactive
HCV-positive sera 5% 6.7% 76.7%
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The overall reactivity of NS4/3 with IgG 1 IgM was
analyzed using well-characterized seroconversion pan-
els (serological panels 4811B, 4813, 4814, and PHV901)
(Table 5). All panels revealed a high reactivity with NS4/3
with acute sera. It is of special interest for the early
diagnosis of HCV that all tested seroconversion panels
had transient, acute-phase IgM anti-HCV NS4/3 detected
coincidentally or earlier than active IgG anti-HCV NS4/3
response. In contrast the linear epitopes NS4/1 and
NS4/2 of the 5-1-1-antigen were not found to be of es-
sential use in early anti-HCV diagnosis.
Immunologic cross-reactivity of NS4/3 with human
blood donors
The specificity of the NS4/3 epitope (aa 1924–1941)
was further investigated. Sera (2050) of asymptomatic
blood donors were screened for reactivity with NS4/3
with the streptavidin–biotin ELISA. Thereby, 21 speci-
mens were identified as reactive only with NS4/3. They
could not be confirmed by reactivity with the HCV-anti-
gens C22-c, C33-c, and C100-3, not including the car-
boxyl terminal NS4-3 epitope. Only 2 of 2050 and 0 of
2050 specimens, not confirmed to be anti-HCV-positive
with FDA-approved anti-HCV assays, were found to be
reactive only with NS4/1 (aa 1712–1720) and NS4/2 (aa
1730–1738), respectively.
By screening a further panel of 1000 sera of asymp-
tomatic blood donors nine specimens were found to be
reactive only with NS4/3 and could not be confirmed with
FDA-approved anti-HCV assays. There were 1/1000 and
0/1000 sera, not confirmed to be anti-HCV-positive with
FDA-approved anti-HCV assays, found to be reactive
with NS4/1 (aa 1712–1720) and NS4/2 (aa 1730–1738),
respectively, only.
Sequence homology of NS4/3 to proteins not derived
from HCV
A sequence data base search for similarities by align-
ing the core sequence of NS4/3 (HCV-1, genotype1, sub-
type 1a) HVSPTHYVPE with proteins not originating from
HCV revealed several sequences with 20.0–60.0%. Ana-
lyzing the reactivity of these peptides with a panel of 23
anti-HCV-positive sera we found that 78% of the sera
were reactive with a peptide derived from Bacillus sub-
tilis; 17% of sera were reactive with a peptide derived
from HSV1. Peptides with sequences derived from more
exotic origins, such as goldfish or paramecium, reacted
with 13 and 26%, respectively, of human anti-HCV-posi-
tive sera (Table 6).
Elongation of the 10-mer NS4/3 resulted in an optimi-
zation of specificity with asymptomatic blood donors. In
order to explain the remaining unspecific reactivities of
the 18-mer NS4/3 peptide we continued our search for
sequence homologies of nonspecific polypeptides in an
18-amino-acid overlap. We found sequence homologies
of more than 40% with several nonspecific proteins (de-
TABLE 4
Sequence Alignment of the Linear Hepatitis C Viral Epitope Sequences NS4/1 (aa 1710–1724), NS4/2 (aa 1722–1739),
and NS4/2 (aa 1722–1739) of Nonstructural Region 4
1 HCV-J (Type 1b)
2 HCV-J6 (Type 2a)
3 NZL1 (Type 3a)
4 EG-1 (Type 4a)
5 BE95 (Type 5a)
6 T3 950 (Type 6a)
Alignment of sequences:
NS4/1 NS4/2 NS4/3
1710 1727 1722 1739 1924 1941
ECASHLPYIEQGMQLAEQ 18 1 MQLAEQFKQKALGLLQTA 18 1 SRGNHVSPTHYVPESDAA 18 1
ECASRAALIEEGQRIAEM 18 2 GRIAEMLKSKIQGLLQQA 18 2 SRGNHVAPTHYVTESDAS 18 2
ECSQAAPYIEQAQVIAHQ 18 3 QVIAHQFKEKILGLLQRA 18 3 GNHVSPTHYVPESDAA 16 3
* * ** * * * * * * * * * * * * * * * . * * * * * . * * * * .
*Number of completely conserved sites
within genotype 1–3: 5
*Number of completely conserved sites
within genotype 1–3: 8
*Number of completely conserved sites
within genotype 1–3: 15
ECSKHLPLVEHGLQLAEQ 18 4 LQLAEQFKQKAAGLLSIA 18 4 ------------------a 0 4
ECSASLPYMDETRAIAGQ 18 5 RAIAGQFKEKVLGFISTT 18 5 ------------------a 0 5
ECSRHIPYLAEGQQIAEQ 18 6 QQIAEQFRQKVLGLLQAS 18 6 ------------------a 0 6
** * * * *
*Number of completely conserved sites
within genotype 1–6: 3
*Number of completely conserved sites
within genotype 1–6: 3
a The NS4/3 sequences of types 4, 5, and 6 are not yet published.
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rived from cytomegalovirus, Escherichia coli, and several
human immunoglobulin chains). As the highest se-
quence homology was found with a sequence of an
immediate-early protein of murine cytomegalovirus
(IEP2), we checked the reactivity of NS4/3 (18-mer) with
a panel of human sera of patients with cytomegalovirus
infections. Eight percent (5/60) of sera of patients in-
fected with cytomegalovirus, but not with HCV, were false
reactive with the HCV peptide NS4/3, possibly due to
immunological cross-reactivities with cytomegalovirus.
DISCUSSION
The epitopes identified by the authors of the present
work by use of two different strategies (epitope scan with
12-mer pin peptides with a 9-amino-acid overlap and
with 25-mer biotinylated peptides with a 15-amino-acid
overlap) correspond well to the location of continuous
epitopes described by other authors. A systematic over-
view of linear B-cell epitopes of the nonstructural region
4 of HCV was given by several authors (Table 7). Corre-
spondingly, most of them describe the mapping of two or
three immunodominant epitopes located within the se-
quence of the C100-3 antigen, predominantly at the se-
quence positions of the 5-1-1 antigen (Cerino and Mon-
delli, 1991; Simmonds et al., 1993; Sa¨llberg et al., 1993).
Only three authors mentioned the presence of a further
epitope with major immunoreactivity, located outside the
C100-3 antigen at the C-terminal part of the NS4 protein
(Park et al., 1995; Flegelova´ et al., 1994; Khudyakov et al.,
1995). The potential diagnostic importance of this
epitope was not investigated.
The present work was intended to give an immuno-
logical characterization of a linear HCV NS4 epitope
showing major immunoreactivity (NS4/3), located outsite
the NS4-antigens (C100-3, 5-1-1) which are typically used
TABLE 5
Assessment of the IgG Anti-HCV NS4/1 and NS4/2 Responses and of the IgM and IgG Anti-HCV NS4/3 Responses
with Well-Characterized Seroconversion Panels
Date of follow-ups
NS4/1
IgG
coI
NS4/2
IgG
coI
NS4/3
IgG
coI
NS4/3
IgM
coI
NS4/3
IgG 1 IgM
(Elecsys) coI
Panel 4811B
8/25/88 05 0.3 0.3 0.4 1.2 1.2
8/29/88 06 0.3 0.3 0.6 4.4 9.3
9/14/88 07 0.3 0.3 1.3 7.7 24.4
5/10/88 08 0.3 0.3 1.4 1.2 2.0
19/10/88 09 0.3 0.3 10.6 0.8 1.6
Panel 4813
8/30/88 11 0.3 0.3 0.3 0.3 0.3
9/28/88 12 0.3 0.4 0.4 0.3 0.3
11/9/88 13 0.9 0.4 6.0 1.4 2.7
11/22/88 14 1.1 0.4 10.0 2.3 3.3
12/6/88 15 1.0 0.4 10.0 1.6 3.4
Panel 4814
11/17/92 05 0.2 0.3 0.2 0.3 0.4
11/20/92 06 0.3 0.3 0.2 0.2 0.4
12/08/92 07 0.2 0.3 5.1 5.4 49.0
12/17/92 08 0.2 0.3 6.5 7.5 52.6
21/12/92 09 0.2 0.3 9.3 8.0 49.0
Panel PHV 901
23/09/93 01 n.d. n.d. 0.2 0.4 0.3
27/11/93 02 n.d. n.d. 0.2 0.4 0.3
29/12/93 03 n.d. n.d. 0.4 0.7 13.2
31/12/93 04 n.d. n.d. 0.4 0.8 13.7
05/01/94 05 n.d. n.d. 0.5 1.0 7.4
07/01/94 06 n.d. n.d. 13.0 1.0 n.d.
Note. coI.: signal/signal negative serum threefold.
TABLE 6
Sequence Comparison of the NS4/3 Epitope (aa 1928–1937) with
non-HCV Protein Sequences and Its Cross-reactivity with 23 HCV-
Positive Sera
Origin Sequence Reactivity with P/N
HCV NS4/3 (aa
1928–1937) HVSPTHYVPE 20/23 22.7 (8.1–34.0)
Bacillus subtilis KVSDTHYVKS 18/23 14.1 (5.1–26.8)
HSV Typ1 WAVPTRFLP 4/23 15.1 (5.5–24.7)
Paramecium
primaurella TVSPNHYVCV 6/23 10.3 (5.9–22.2)
Goldfish RSPSTHYMPE 3/23 15.8 (7.8–20.7)
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in FDA-approved anti-HCV assays. Due to a systematic
minimization of the NS4/3 sequence it appears that the
core epitope is represented by just three amino acids:
PTH and the presence of S at the amino terminus or Y at
the carboxy terminus restores virtually all the activity.
Thus the minimal epitope might be defined as a pen-
tamer: SPTHY (aa 1930–34). The sequence of NS4/3 was
found to show a high homogenicity within the known
sequences of various HCV subtypes. Due to its broad
reactivity with sera from various geographic origins
NS4/3 is well suited for anti-HCV screening. To the con-
trary, the sequences of the NS4/1 and NS4/2 epitopes
were found to show a great degree of sequence variation
within the various subtypes, thus being more suited for
subtyping than for diagnosis of a broad spectrum of
specimens of different origins (Nagayama et al., 1993;
Simmonds et al., 1993; Kraas et al., 1996).
Antibodies to the HCV C100-3 antigen were found to
appear rather late after infection with HCV (Alter, 1994).
In contrast to the linear epitopes located within the 5-1-1
sequence (NS4/0, NS4/1, NS4/2) showing immunological
reactivity only to patient sera of the chronic stage of HCV
infection, NS4/3 was shown to be highly reactive to
low-affinity IgM antibodies present during the acute
phase of HCV infection. IgM antibody response in acute
hepatitis C viral infection was up to now described as
limited to the detection of IgM anti-HCV core and in rare
cases to detection of anti-HCV NS3 (Clemens et al., 1992;
Chen et al., 1992). NS4/3 was further demonstrated to be
reactive with naturally occurring antibodies of asymp-
tomatic blood donor specimens. The sequence of NS4/3
was found to have a moderate degree of sequence
homology (40 to 60% homology, depending on a 10- or
18-amino-acid core sequence) with nonspecific polypep-
tides originating from organisms as different as human,
viruses, and bacteria. Screening anti-HCV-negative,
asymptomatic blood donors with 10- and 18-mer pep-
tides representing the NS4/3 epitope (aa 1928–1938 and
1924–1941, respectively) resulted in a high degree of
immunological cross-reactivity, especially with the
shorter peptide. Some of the ‘‘false positive reactivities’’
of the 18-mer NS4/3 peptide with asymptomatic blood
donors, not being confirmed with FDA-approved anti-
HCV assays without the NS4/3 epitope, may be ex-
plained by recognition of very early seroconversion an-
tibodies. This is substantiated by the finding that some of
the anti-NS4/3 only specimens contained low titers of
HCV RNA. The high degree of nonspecificity of the NS4/3
epitope may be further explained by sequence similari-
ties to CMV immediate-early proteins. This may be cir-
cumvented by blocking nonspecific binding by addition
of peptides with corresponding CMV sequences.
Nevertheless it appears a contradictory purpose to
assess a maximal sensitivity with the detection of the
low-affinity early immune response and at the same time
minimal immunological cross-reactivities. Low-affinity
antibodies with immunological cross-reactivities have
been described for various infectious agents (Rodman et
al., 1993; Potasman et al., 1986). A HCV core epitope was
found to be reactive with seroconversion antibodies, but
to have further nonspecific reactivities (Tobler et al.,
1996; Seidel et al., 1998). Rodman et al. (1993), explaining
the occurrence of low-affinity antibodies in HIV-negative
human sera with nonspecific reactivities to the HIV TAT
protein. A relationship of those natural antibodies with
resistance to progression of HIV pathogenesis is sug-
gested. This might also hold true for other infectious
agents.
MATERIALS AND METHODS
Synthesis of pin-bound peptides
Peptides were synthesized on polyethylene pins on
a multiple peptide synthesizer (Zinsser SMPS 350
equipped for automated pin synthesis, Wiesmu¨ller et
al., 1992). DIC/HOBT activation was used with a 200-
fold excess of Fmoc amino acid derivates. A synthesis
cycle consisted of the following steps: Deprotection
with 10% piperidine in DMF for 30 min, washing (93
DMF, 1 3 1% acetic acid in DMF for 30 min), drying
(vacuum), coupling (20 mmol amino acid, DIC and
HOBT, 90 min coupling time), washing (33 DMF, 33
methanol), and drying. All peptides were capped N-
terminally with acetic anhydride.
Pin ELISA (for antibodies of the IgG class)
All reactions were performed with the pin plates being
placed in round-bottom microtiter plates (Gombert et al.,
1991). Briefly, pin plates were incubated with blocking
buffer for 2 h at 37°C and then allowed to interact with
human specimens diluted 1:500 in blocking buffer over-
TABLE 7
Sequence Comparison of Published Epitopes of the Hepatitis C
Virus NS4 Region: aa 1620–2016
5-1-1: 1683 – 1735
NS4/0 NS4/1 NS4/2 NS4/3
Present work 1689–1706 1710–1727 1722–1739
1924–1941
Cerino et al.
(1991) 1688–1705
Simmonds et al.
(1993) 1691–1708 1710–1728 1731–1744
Flegelova et al.
(1994) 1691–1714 1915–1938
Sa¨llberg et al.
(1993) 1684 – 1751
Khudyakov et al.
(1995) 1689 – 1730 1921–1940
Park et al.
(1995) 1694–1713 1719–1735 1738–1756
1924–1943
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night at 4°C. Antigenic activity of peptides was identified
using affinity-purified antibodies conjugated to horserad-
ish peroxidase. Pins were cleaned by sonification two
times with disruption buffer for 20 min at 37°C and by
sonification two times with water for 20 min at 50°C.
Synthesis of biotinylated peptides
Biotinylated peptide amides were synthesized on a
simultaneous multiple peptide synthesizer (SMP 350,
Zinsser analytic, Frankfurt) using Fmoc chemistry. The
synthesis resin was a Wang resin carrying the 5-(29-
aminomethyl-39,59-dimethoxyphenoxy)valeric acid (ADVP)
linker (Ihlenfeldt, 1995). Fmoc-protected amino acid de-
rivates were activated with DIC/HOBt in DMF and cou-
pled in a 10-fold excess. Coupling and deprotection
times were 60 and 25 min, respectively. All peptides were
elongated by the spacer amino acids Na-Fmoc-b-alanin,
Na-Fmoc-e-aminocaproicacid, Na-Fmoc-b-alanin, and
Na-Fmoc-e-lysin before biotin was coupled finally to the
N-terminus.
Streptavidin–biotin ELISA (for antibodies of the
IgG class)
In general epitope mapping was performed with the
Boehringer Mannheim Epitope Mapping Kit (introduction
in preparation). It contains the complete set of buffers
and streptavidin-coated microtiter plates needed for the
streptavidin–biotin ELISA (for antibodies of the IgG
class). Briefly, biotinylated peptides at a concentration of
50 ng per streptavidin-coated microtiter well were al-
lowed to interact with human specimens diluted 1:20 in
incubation buffer for 1 h at room temperature. Antigenic
activity of peptides was identified using affinity-purified
antibodies conjugated to horseradish peroxidase.
Streptavidin–biotin ELISA (for antibodies of the
IgM class)
A m-capture IgM assay was performed. Briefly, biotin-
ylated anti-human IgM was allowed to interact with hu-
man specimens, possibly containing virus-specific IgM,
in streptavidin-coated assay tubes in incubation buffer
for 1 h at 25°C. Then digoxigenylated peptides were
added and allowed to incubate for 1 h at 25°C; the
antigenic activity of peptides was identified using affinity-
purified anti-digoxin antibodies conjugated to horserad-
ish peroxidase.
Streptavidin–biotin Elecsys assay (for antibodies the
IgG and IgM classes, bridging concept)
The Boehringer Mannheim Elecsys assay is a double
antigen one-step immunoassay. Briefly, biotinylated and
with Ruthenium (II)-bis-(2,29-bipyridyl)-[4(49-methyl-2,29-
bipyridyl)]-butyl labeled peptides with the same antigenic
sequences at concentrations of 50 ng of each differential
labeled peptide per tube were allowed to interact with
human specimens diluted 1:10 in incubation buffer for 10
min at 37°C. Afterward, immunological complexes were
captured by incubation for 10 min at 37°C with strepta-
vidin-coated magnetic beads. Then the reaction mixture
was aspirated into the measuring cell, where the beads
were fixed by a magnet to the electrode surface. After
removal of unbound label by a washing step, voltage was
applied to the electrode and chemiluminescent emission
was recorded by a photomultiplier.
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